Baird analyst Brian Skorney upgraded Regeneron Pharma (NASDAQ: REGN) from Neutral to Outperform with a price target of $410.00.The analyst ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Hot Comments Hot Upgrades Upgrades